Publications for Lisa Bero
Publications for Lisa Bero
2016
Alexander, P., Gionfriddo, M., Li, S., Bero, L.,
Stoltzfus, R., Neumann, I., Brito, J., Djulbegovic,
B., Montori, V., Norris, S., et al (2016). A
number of factors explain why WHO guideline
developers make strong recommendations
inconsistent with GRADE guidance. Journal of
Clinical Epidemiology, 70, 111-122. <a
href="http://dx.doi.org/10.1016/j.jclinepi.2015.0
9.006">[More Information]</a>
Wang, Z., Norris, S., Bero, L. (2016).
Implementation plans included in World Health
Organisation guidelines. Implementation
Science, 11(1), 1-9. <a
href="http://dx.doi.org/10.1186/s13012-016-044
0-4">[More Information]</a>
Alexander, P., Brito, J., Neumann, I., Gionfriddo,
M., Bero, L., Djulbegovic, B., Stoltzfus, R.,
Montori, V., Norris, S., Schunemann, H., et al
(2016). World Health Organization strong
recommendations based on low-quality evidence
(study quality) are frequent and often
inconsistent with GRADE guidance. Journal of
Clinical Epidemiology, 72, 98-106. <a
href="http://dx.doi.org/10.1016/j.jclinepi.2014.1
0.011">[More Information]</a>
2015
Chiu, Y., Bero, L., Hessol, N., Lexchin, J.,
Harrington, C. (2015). A literature review of
clinical outcomes associated with antipsychotic
medication use in North American nursing home
residents. Health Policy, 119(6), 802-813. <a
href="http://dx.doi.org/10.1016/j.healthpol.2015.
02.014">[More Information]</a>
Tran, D., Bero, L. (2015). Barriers and
facilitators to the quality use of essential
medicines for maternal health in low-resource
countries: An Ishikawa framework. Journal of
Global Health, 5(1), 1-9. <a
href="http://dx.doi.org/10.7189/jogh.05.010406"
>[More Information]</a>
Tuller, D., Bero, L. (2015). Big Tobacco and
Drugstore Chains: A Long, Cozy Relationship.
JAMA Oncology, 1(9), 1215-1216. <a
href="http://dx.doi.org/10.1001/jamaoncol.2015.
2621">[More Information]</a>
Hill, S., Bero, L., McColl, G., Roughead, E.
(2015). Expensive medicines: ensuring objective
appraisal and equitable access. Bulletin of the
World Health Organization, 93(1), 4-4A. <a
href="http://dx.doi.org/10.2471/BLT.14.148924"
>[More Information]</a>
Anglemyer, A., Krauth, D., Bero, L. (2015).
Industry sponsorship and publication bias among
animal studies evaluating the effects of statins on
atherosclerosis and bone outcomes: A
meta-analysis. BMC Medical Research
Methodology, 15(1), 1-10. <a
href="http://dx.doi.org/10.1186/s12874-015-000
8-z">[More Information]</a>
Elliott, J., Grimshaw, J., Altman, R., Bero, L.,
Goodman, S., Henry, D., Macleod, M., Tovey,
D., Tugwell, P., White, H., et al (2015).
Informatics: Make sense of health data. Nature,
527(7576), 31-32. <a
href="http://dx.doi.org/10.1038/527031a">[More
Information]</a>
Siler, K., Lee, K., Bero, L. (2015). Measuring the
effectiveness of scientific gatekeeping.
Proceedings of the National Academy of
Sciences of the United States of America (PNAS),
112(2), 360-365. <a
href="http://dx.doi.org/10.1073/pnas.141821811
2">[More Information]</a>
Moynihan, R., Nickel, B., Hersch, J., Beller, E.,
Doust, J., Compton, S., Barratt, A., Bero, L.,
McCaffery, K. (2015). Public Opinions about
Overdiagnosis: A National Community Survey.
PloS One, 10(5), 1-13. <a
href="http://dx.doi.org/10.1371/journal.pone.012
5165">[More Information]</a>
Bero, L., Siler, K., Lee, K. (2015). Reply to
Margalida and Colomer: Science should strive to
prevent mistakes, not corrections. Proceedings of
the National Academy of Sciences of the United
States of America (PNAS), 112(13),
E1512-E1512. <a
href="http://dx.doi.org/10.1073/pnas.150137111
2">[More Information]</a>
Chang, L., Dhruva, S., Chu, J., Bero, L.,
Redberg, R. (2015). Selective reporting in trials
of high risk cardiovascular devices: Cross
sectional comparison between premarket
approval summaries and published reports. BMJ,
350, 1-7. <a
href="http://dx.doi.org/10.1136/bmj.h2613">[M
ore Information]</a>
Mahady, S., Schlub, T., Bero, L., Moher, D.,
Tovey, D., George, J., Craig, J. (2015). Side
effects are incompletely reported among
systematic reviews in gastroenterology. Journal
of Clinical Epidemiology, 68(2), 144-153. <a
href="http://dx.doi.org/10.1016/j.jclinepi.2014.0
6.016">[More Information]</a>
Grundy, Q., Bero, L. (2015). Systematic reviews
of health-related mobile apps: Can it be done?
Cochrane Symposium 2015, Melbourne,
Australia: The Cochrane Library.
Schroll, J., Abdel-Sattar, M., Bero, L. (2015).
The Food and Drug Administration reports
provided more data but were more difficult to
use than the European Medicines Agency
Publications for Lisa Bero
reports. Journal of Clinical Epidemiology, 68(1),
102-107. <a
href="http://dx.doi.org/10.1016/j.jclinepi.2014.0
6.019">[More Information]</a>
Abdel-Sattar, M., Krauth, D., Anglemyer, A.,
Bero, L. (2015). The relationship between risk of
bias criteria, research outcomes, and study
sponsorship in a cohort of preclinical
thiazolidinedione animal studies: a
meta-analysis. Evidence-based Preclinical
Medicine, 1(1), 11-20. <a
href="http://dx.doi.org/10.1002/ebm2.5">[More
Information]</a>
2014
Bero, L. (2014). Bias related to funding source in
statin trials. BMJ, 349, 1-2. <a
href="http://dx.doi.org/10.1136/bmj.g5949">[M
ore Information]</a>
Forsyth, S., Odierna, D., Krauth, D., Bero, L.
(2014). Conflicts of interest and critiques of the
use of
systematic reviews in policymaking: an analysis
of opinion articles. Systematic Reviews, 3(1),
1-11. <a
href="http://dx.doi.org/10.1186/2046-4053-3-12
2">[More Information]</a>
Anglemyer, A., Horvath, H., Bero, L. (2014).
Healthcare outcomes assessed with observational
study designs compared with those assessed in
randomized trials. Cochrane Database of
Systematic Reviews, 4, 1-44. <a
href="http://dx.doi.org/10.1002/14651858.MR00
0034.pub2">[More Information]</a>
Krauth, D., Anglemyer, A., Philipps, R., Bero, L.
(2014). Nonindustry-Sponsored Preclinical
Studies on Statins Yield Greater Efficacy
Estimates Than Industry-Sponsored Studies: A
Meta-Analysis. PLoS Biology, 12(1), 1-10. <a
href="http://dx.doi.org/10.1371/journal.pbio.100
1770">[More Information]</a>
Magrini, N., Robertson, J., de Joncheere, K.,
Bero, L. (2014). On WHO's essential medicines
process and transparency. BMJ, 349, 1-1. <a
href="http://dx.doi.org/10.1136/bmj.g5637">[M
ore Information]</a>
Coralic, Z., Kanzaria, H., Bero, L., Stein, J.
(2014). Staff Perceptions of an On-site Clinical
Pharmacist Program in an Academic Emergency
Department after One Year. Western Journal of
Emergency Medicine, 15(2), 205-210. <a
href="http://dx.doi.org/10.5811/westjem.2013.11
.18069">[More Information]</a>
Apollonio, D., Glantz, S., Bero, L. (2014). Term
limits and the tobacco industry. Social Science
and Medicine, 104, 1-5. <a
href="http://dx.doi.org/10.1016/j.socscimed.2013
.11.005">[More Information]</a>
Bero, L. (2014). What is in a name?
Nonfinancial influences on the outcomes of
systematic reviews and guidelines. Journal of
Clinical Epidemiology, 67(11), 1239-1241. <a
href="http://dx.doi.org/10.1016/j.jclinepi.2014.0
6.015">[More Information]</a>
Alexander, P., Bero, L., Montori, V., Brito, J.,
Stoltzfus, R., Djulbegovic, B., Neumann, I.,
Rave, S., Guyatt, G. (2014). World Health
Organization recommendations are often strong
based on low confidence in effect estimates.
Journal of Clinical Epidemiology, 67(6),
629-634. <a
href="http://dx.doi.org/10.1016/j.jclinepi.2013.0
9.020">[More Information]</a>
2013
Chahal, H., St. Fort, N., Bero, L. (2013).
Availability, prices and affordability of essential
medicines in Haiti. Journal of Global Health,
3(2), 1-11. <a
href="http://dx.doi.org/10.7189/jogh.03.020405"
>[More Information]</a>
Moynihan, R., Cooke, G., Doust, J., Bero, L.,
Hill, S., Glasziou, P. (2013). Expanding Disease
Definitions in Guidelines and Expert Panel Ties
to Industry: A Cross-sectional Study of Common
Conditions in the United States. PLoS Medicine,
10(8), 1-12. <a
href="http://dx.doi.org/10.1371/journal.pmed.10
01500">[More Information]</a>
Krauth, D., Woodruff, T., Bero, L. (2013).
Instruments for Assessing Risk of Bias and Other
Methodological Criteria of Published Animal
Studies: A Systematic Review. Environmental
Health Perspectives, 121(9), 985-992. <a
href="http://dx.doi.org/10.1289/ehp.1206389">[
More Information]</a>
Grundy, Q., Bero, L., Malone, R. (2013).
Interactions between Non-Physician Clinicians
and Industry: A Systematic Review. PLoS
Medicine, 10(11), 1-13. <a
href="http://dx.doi.org/10.1371/journal.pmed.10
01561">[More Information]</a>
Nguyen, N., Bero, L. (2013). Medicaid Drug
Selection Committees and Inadequate
Management of Conflicts of Interest. JAMA
Internal Medicine, 173(5), 338-343. <a
href="http://dx.doi.org/10.1001/jamainternmed.2
013.2522">[More Information]</a>
Conway, J., Bero, L., Ondari, C., Wasan, K.
(2013). Review of the Quality of Pediatric
Medications in Developing Countries. Journal of
Pharmaceutical Sciences, 102(5), 1419-1433. <a
href="http://dx.doi.org/10.1002/jps.23474">[Mor
e Information]</a>
Publications for Lisa Bero
Schroll, J., Bero, L., Gøtzsche, P. (2013).
Searching for unpublished data for Cochrane
reviews: cross sectional study. BMJ, 346(7913),
1-11. <a
href="http://dx.doi.org/10.1136/bmj.f2231">[Mo
re Information]</a>
Wolfe, N., Gøtzsche, P., Bero, L. (2013).
Strategies for obtaining unpublished drug trial
data: a qualitative interview study. Systematic
Reviews, 2, 1-11. <a
href="http://dx.doi.org/10.1186/2046-4053-2-31"
>[More Information]</a>
Odierna, D., Forsyth, S., White, J., Bero, L.
(2013). The Cycle of Bias in Health Research: A
Framework and Toolbox for Critical Appraisal
Training. Accountability in Research: policies
and quality assurance, 20(2), 127-141. <a
href="http://dx.doi.org/10.1080/08989621.2013.
768931">[More Information]</a>
Pande, S., Hiller, J., Nkansah, N., Bero, L.
(2013). The effect of pharmacist-provided
non-dispensing services on patient outcomes,
health service utilisation and costs in low- and
middle-income countries. Cochrane Database of
Systematic Reviews, 2, 1-72. <a
href="http://dx.doi.org/10.1002/14651858.CD01
0398">[More Information]</a>
Bero, L., Hill, S., Habicht, J., Mathiesen, M.,
Starkopf, J. (2013). The updated clinical
guideline development process in Estonia is an
efficient method for developing evidence-based
guidelines. Journal of Clinical Epidemiology,
66(2), 132-139. <a
href="http://dx.doi.org/10.1016/j.jclinepi.2012.0
7.007">[More Information]</a>
Bero, L. (2013). Tobacco industry manipulation
of research. In David Gee, Philippe Grandjean,
Steffen Foss Hansen, Sybille van den Hove, et
al (Eds.), Late lessons from early warnings:
science, precaution, innovation, (pp. 151-178).
Copenhagen: European Environmental Agency.
2012
Bero, L. (2012). Assessing Risk of Bias.
Australian Pharmaceutical Benefits Advisory
Committee's April Meeting.
Norris, S., Burda, B., Holmer, H., Ogden, L., Fu,
R., Bero, L., Schünemann, H., Deyo, R. (2012).
Author’s specialty and conflicts of interest
contribute to conflicting guidelines for screening
mammography. Journal of Clinical
Epidemiology, 65(7), 725-733. <a
href="http://dx.doi.org/10.1016/j.jclinepi.2011.1
2.011">[More Information]</a>
Anson, A., Ramay, B., de Esparza, A., Bero, L.
(2012). Availability, prices and affordability of
the World Health Organization’s essential
medicines for children in Guatemala.
Globalization and Health, 8, 1-10. <a
href="http://dx.doi.org/10.1186/1744-8603-8-22"
>[More Information]</a>
Taba, P., Rosenthal, M., Habicht, J., Tarien, H.,
Mathiesen, M., Hill, S., Bero, L. (2012). Barriers
and facilitators to the implementation of clinical
practice guidelines: A cross-sectional survey
among physicians in Estonia. BMC Health
Services Research, 12(1), 1-7. <a
href="http://dx.doi.org/10.1186/1472-6963-12-4
55">[More Information]</a>
Hart, B., Lundh, A., Bero, L. (2012). Effect of
reporting bias on meta-analyses of drug trials:
reanalysis of meta-analyses. BMJ, 344(7838),
1-11. <a
href="http://dx.doi.org/10.1136/bmj.d7202">[M
ore Information]</a>
Lundh, A., Sismondo, S., Lexchin, J., Busuioc,
O., Bero, L. (2012). Industry sponsorship and
research outcome. Cochrane Database of
Systematic Reviews, 12(2012), 1-88. <a
href="http://dx.doi.org/10.1002/14651858.MR00
0033.pub2">[More Information]</a>
Hill, S., Yang, A., Bero, L. (2012). Priority
Medicines for Maternal and Child Health: A
Global Survey of National Essential Medicines
Lists. PloS One, 7(5), 1-6. <a
href="http://dx.doi.org/10.1371/journal.pone.003
8055">[More Information]</a>
Roseman, M., Turner, E., Lexchin, J., Coyne, J.,
Bero, L., Thombs, B. (2012). Reporting of
conflicts of interest from drug trials in Cochrane
reviews: cross sectional study. BMJ, 345, 1-10.
<a
href="http://dx.doi.org/10.1136/bmj.e5155">[Mo
re Information]</a>
Bero, L. (2012). Selective outcome reporting:
Impact on Drug Evaluation. Australian
Pharmaceutical Benefits Advisory Committee's
April Meeting.
Malone, R., Grundy, Q., Bero, L. (2012).
Tobacco industry denormalisation as a tobacco
control intervention: a review. Tobacco Control,
21(2), 162-170. <a
href="http://dx.doi.org/10.1136/tobaccocontrol-2
011-050200">[More Information]</a>
2011
Woodruff, T., Sutton, P., Cogliano, V., Guyton,
K., Quint, J., Zeise, L., Balk, J., Bero, L., Conry,
J., Fox, D., et al (2011). An evidence-based
medicine methodology to bridge the gap between
clinical and environmental health sciences.
Health Affairs, 30(5), 931-937. <a
href="http://dx.doi.org/10.1377/hlthaff.2010.121
9">[More Information]</a>
Millar, T., Wong, S., Odierna, D., Bero, L.
Publications for Lisa Bero
(2011). Applying the Essential Medicines
Concept to US Preferred Drug Lists. American
Journal of Public Health, 101(8), 1444-1448. <a
href="http://dx.doi.org/10.2105/AJPH.2010.3000
54">[More Information]</a>
2010
White, J., Bero, L. (2010). Corporate
manipulation of research: Strategies are similar
across five industries. Stanford Law and Policy
Review, 21(1), 105-134.
Walleser, S., Hill, S., Bero, L. (2011).
Characteristics and quality of reporting of cluster
randomized trials in children: reporting needs
improvement. Journal of Clinical Epidemiology,
64(12), 1331-1340. <a
href="http://dx.doi.org/10.1016/j.jclinepi.2011.0
4.006">[More Information]</a>
Smith, M., Bero, L., Carber, L. (2010). Could
chiropractors screen for adverse drug events in
the community? Survey of US chiropractors.
Chiropractic and Osteopathy, 18(2010), 1-8. <a
href="http://dx.doi.org/10.1186/1746-1340-18-3
0">[More Information]</a>
Dhruva, S., Bero, L., Redberg, R. (2011). Gender
Bias in Studies for Food and Drug
Administration Premarket Approval of
Cardiovascular Devices. Circulation.
Cardiovascular Quality and Outcomes, 4(2),
165-171. <a
href="http://dx.doi.org/10.1161/CIRCOUTCOM
ES.110.958215">[More Information]</a>
Nkansah, N., Mostovetsky, O., Yu, C., Chheng,
T., Beney, J., Bond, C., Bero, L. (2010). Effect
of outpatient pharmacists’ non-dispensing roles
on patient outcomes and prescribing patterns.
Cochrane Database of Systematic Reviews,
7(2010). <a
href="http://dx.doi.org/10.1002/14651858.CD00
0336.pub2">[More Information]</a>
Bero, L. (2011). Ghosts, guests and other
distortions of authorship in medical and scientific
journals. COPE (Committee on Publication
Ethics) North American Seminar and Forum,
San Diego, North America.
Bero, L. (2010). Evidence: Can we Trust it?
Evidence on trial: has it made an impact on
health?.
Chen, C., Dhruva, S., Bero, L., Redberg, R.
(2011). Inclusion of Training Patients in US
Food and Drug Administration Premarket
Approval Cardiovascular Device Studies.
Archives of Internal Medicine, 171(6), 534-539.
<a
href="http://dx.doi.org/10.1001/archinternmed.2
010.445">[More Information]</a>
Krleža-Jeriç, K., Lemmens, T., Reveiz, L.,
Cuervo, L., Bero, L. (2011). Prospective
registration and results disclosure of clinical
trials in the Americas: a roadmap toward
transparency. Revista Panamericana de Salud
Publica-Pan (American Journal of Public
Health), 30(1), 87-96.
Roseman, M., Milette, K., Bero, L., Coyne, J.,
Lexchin, J., Turner, E., Thombs, B. (2011).
Reporting of Conflicts of Interest in
Meta-analyses of Trials of Pharmacological
Treatments. JAMA: The Journal of the American
Medical Association, 305(10), 1008-1017. <a
href="http://dx.doi.org/10.1001/jama.2011.257">
[More Information]</a>
Ridge, A., Bero, L., Hill, S. (2010). Identifying
barriers to the availability and use of Magnesium
Sulphate Injection in resource poor countries: A
case study in Zambia. BMC Health Services
Research, 10, 1-9. <a
href="http://dx.doi.org/10.1186/1472-6963-10-3
40">[More Information]</a>
Bero, L. (2010). International ethical guidelines
regarding inclusion of children in clinical trials.
StaR Child Health Conference.
Robertson, J., Walkom, E., Moynihan, R., Bero,
L., Henry, D. (2010). Pharmaceutical industry
funding of educational events for pharmacists in
Australia: an analysis of data from the first 6
months of a mandatory disclosure programme.
International Journal of Pharmacy Practice,
18(2), 88-92. <a
href="http://dx.doi.org/10.1211/ijpp/18.02.0003"
>[More Information]</a>
Bero, L. (2010). Taming the beast: managing
conflicts of interest in research. World Health
Organisation Conference.
Bero, L. (2011). The Cochrane Collaboration and
Clinical Practice Guidelines. Estonian Health
Insurance Fund and World Health Organization.
Tallin, Estonia (September 7).
Montini, T., George, A., Martin-Mollard, M.,
Bero, L. (2010). The role of public participation
in public health initiatives: An analysis of the
WHO Framework Convention on Tobacco
Control. Global Public Health, 5(1), 48-61. <a
href="http://dx.doi.org/10.1080/1744169080216
4391">[More Information]</a>
Van den Ham, R., Bero, L., Laing, R. (2011).
The world medicines situation report 2011:
Selection of Essential Medicines,
WHO/EMP/MIE/2011.2.8, (pp. 1 - 18). Geneva,
Switzerland: World Health Organisation.
Bero, L., Carson, B., Moller, H., Hill, S. (2010).
To give is better than to receive: compliance with
WHO guidelines for drug donations during
2000–2008. Bulletin of the World Health
Organization, 88(12), 922-929. <a
Publications for Lisa Bero
href="http://dx.doi.org/10.2471/BLT.10.079764"
>[More Information]</a>
Cataldo, J., Bero, L., Malone, R. (2010). ‘‘A
delicate diplomatic situation’’: tobacco industry
efforts to gain control of the Framingham Study.
Journal of Clinical Epidemiology, 63(8),
841-853. <a
href="http://dx.doi.org/10.1016/j.jclinepi.2010.0
1.021">[More Information]</a>
2009
Rasmussen, N., Lee, K., Bero, L. (2009).
Association of trial registration with the results
and conclusions of published trials of new
oncology drugs. 6th International Congress on
Peer Review and Biomedical Publication 2009,
Vancouver, British Columbia, Canada. <a
href="http://dx.doi.org/10.1186/1745-6215-10-1
16">[More Information]</a>
Apollonio, D., Bero, L. (2009). Evidence and
argument in policymaking: development of
workplace smoking legislation. BMC Public
Health, 9, 1-10. <a
href="http://dx.doi.org/10.1186/1471-2458-9-18
9">[More Information]</a>
Rattinger, G., Bero, L. (2009). Factors
Associated with Results and Conclusions of
Trials of Thiazolidinediones. PloS One, 4(6),
1-10. <a
href="http://dx.doi.org/10.1371/journal.pone.000
5826">[More Information]</a>
Cook, D., Boyd, E., Grossman, C., Bero, L.
(2009). Journalists and conflicts of interest in
science: Beliefs and practices. Ethics in Science
and Environmental Politics, 9(1), 33-40. <a
href="http://dx.doi.org/10.3354/esep00100">[M
ore Information]</a>
Robertson, J., Moynihan, R., Walkom, E., Bero,
L., Henry, D. (2009). Mandatory Disclosure of
Pharmaceutical Industry-Funded Events for
Health Professionals. PLoS Medicine, 6(11), 1-5.
<a
href="http://dx.doi.org/10.1371/journal.pmed.10
00128">[More Information]</a>
White, J., Bandura, A., Bero, L. (2009). Moral
disengagement in the corporate world.
Accountability in Research: policies and quality
assurance, 16(1), 41-74. <a
href="http://dx.doi.org/10.1080/0898962080268
9847">[More Information]</a>
Vedula, S., Bero, L., Scherer, R., Dickersin, K.
(2009). Outcome Reporting in
Industry-Sponsored Trials Of Gabapentin for
Off-Label Use. The New England Journal of
Medicine, 361(20), 1963-1971. <a
href="http://dx.doi.org/10.1056/NEJMsa0906126
">[More Information]</a>
Kummerfeldt, C., Barnoya, J., Bero, L. (2009).
Philip Morris involvement in the development of
an air quality laboratory in El Salvador. Tobacco
Control, 18(3), 241-244. <a
href="http://dx.doi.org/10.1136/tc.2008.026989"
>[More Information]</a>
Nkansah, N., Nguyen, T., Iraninezhad, H., Bero,
L. (2009). Randomized trials assessing calcium
supplementation in healthy children:
Relationship between industry sponsorship and
study outcomes. Public Health Nutrition, 12(10),
1931-1937. <a
href="http://dx.doi.org/10.1017/S136898000900
487X">[More Information]</a>
Cook, D., Gurugubelli, R., Bero, L. (2009). Risk
Management Policy and Black-Box Warnings: A
Qualitative Analysis of US FDA Proceedings.
Drug Safety, 32(11), 1057-1066. <a
href="http://dx.doi.org/10.2165/11316670-00000
0000-00000">[More Information]</a>
Dhruva, S., Bero, L., Redberg, R. (2009).
Strength of Study Evidence Examined by the
FDA in Premarket Approval of Cardiovascular
Devices. JAMA: The Journal of the American
Medical Association, 302(24), 2679-2685. <a
href="http://dx.doi.org/10.1001/jama.2009.1899"
>[More Information]</a>
Odierna, D., Bero, L. (2009). Systematic reviews
reveal unrepresentative evidence for the
development of drug formularies for poor and
nonwhite populations. Journal of Clinical
Epidemiology, 62(12), 1268-1278. <a
href="http://dx.doi.org/10.1016/j.jclinepi.2009.0
1.009">[More Information]</a>
Bero, L. (2009). Tainted evidence on drugs.
International Cochrane Symposium.
Evidence-based Medicine and Systematic
Reviews: Challenges and Opportunities.
Cook, D., Bero, L. (2009). The Politics of
Smoking in Federal Buildings: An Executive
Order Case Study. American Journal of Public
Health, 99(9), 1588-1595. <a
href="http://dx.doi.org/10.2105/AJPH.2008.1518
29">[More Information]</a>